FDA and EMA approve multiple novel therapies for cancer and rare diseases while new research raises concerns about caffeine, sugar substitutes, and maternal infections

Datopotamab deruxtecan, an antibody-drug conjugate, received FDA approval for certain triple-negative breast cancer patients, expanding treatment options for this aggressive cancer subtype.

The EMA authorized a new oral therapy for idiopathic and progressive pulmonary fibrosis, addressing two fibrotic lung diseases that have historically had limited treatment options available.

EMA granted conditional approval for the first drug targeting severe PIK3CA-related overgrowth disorders in patients aged 2 years and older, offering hope for a previously untreated rare genetic condition.

Camizestrant, a selective estrogen receptor degrader, received EMA backing after phase 3 data demonstrated improved progression-free survival in breast cancer patients when combined with CDK4/6 inhibitors, despite an earlier FDA rejection.

CRISPR-Cas9 gene-editing treatments show promise as potential one-time curative therapies for cardiovascular disease, though long-term safety assessments require additional years of study.

Maternal chikungunya infection during pregnancy was linked to increased hospitalization risk in infants through age 3 in a Brazilian cohort study, with implications for global surveillance and vaccination strategies.

Higher caffeine intake correlated with greater depression severity, though the substance appeared to reduce the association between depression and severe insomnia in a new analysis.

Emerging research indicates sugar substitutes may have underestimated effects on metabolism, gut microbiome composition, and cardiovascular health, contradicting previous safety assumptions about these sweeteners.